The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.
Davis Yuri Torrejon
No relevant relationships to disclose
Serena Di Cosimo
No relevant relationships to disclose
Gessami Sanchez-Olle
No relevant relationships to disclose
Judith Balmaña
No relevant relationships to disclose
Meritxell Bellet
No relevant relationships to disclose
Patricia Gomez
No relevant relationships to disclose
Cristina Saura
No relevant relationships to disclose
Jose Manuel Perez-Garcia
No relevant relationships to disclose
Eva Muñoz-Couselo
No relevant relationships to disclose
Maria Vidal
No relevant relationships to disclose
Vanesa Ortega
No relevant relationships to disclose
Leticia De Mattos-Arruda
No relevant relationships to disclose
Mafalda Oliveira
No relevant relationships to disclose
Nuria Mulet-Margalef
No relevant relationships to disclose
Josep Tabernero
No relevant relationships to disclose
Javier Cortes
No relevant relationships to disclose